关于公司
Immunocore is a focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
GB
未知
未验证公司
业务透明度
- 未验证公司信息
- 向他们的客户询问评论
- 没有回复负面评论